📡 RADAR REPORT
Friday, 13 November 2026 · data as of 2026-11-13 20:22 UTC
ACTIVE TRIALS8,725
P3 READOUTS · 14D15
P3 READOUTS · 30D119
CHANGES · 7D0
LATE >6 MONTHS46%
Phase 3 readouts due · next 14 days
15 trials with an exact primary-completion date in the next two weeks (119 in the next 30 days).
| Date | Trial | Sponsor | Area | N | vs. original plan |
|---|---|---|---|---|---|
| 2026-11-13 | INAVO121 | Hoffmann-La Roche $ROG.SW | Oncology | 420 | -18.6 mo |
| 2026-11-15 | ORCA-V2 | Achieve Life Sciences | Other | 800 | — |
| 2026-11-18 | POETYK SjS-1 | Bristol-Myers Squibb $BMY | Immuno | 774 | +0.0 mo |
| 2026-11-18 | Drugs-SNPs | Medicine Invention Design, Inc | Oncology | 600 | +30.0 mo |
| 2026-11-20 | Pembrolizumab | Merck Sharp & Dohme LLC $MRK | Oncology | 990 | +17.1 mo |
| 2026-11-21 | Cabergoline tablets | Changchun GeneScience Pharmaceutical Co., Ltd. | Cardio-Met | 382 | +14.0 mo |
| 2026-11-23 | Investigational varicella vaccine | GlaxoSmithKline $GSK | Infectious | 750 | +4.4 mo |
| 2026-11-23 | dTpa | GlaxoSmithKline $GSK | Infectious | 102 | — |
| 2026-11-24 | KarXT | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Neuro | 406 | +0.8 mo |
| 2026-11-24 | Avelumab | EMD Serono Research & Development Institute, Inc. $MRK.DE | Oncology | 205 | +33.9 mo |
| 2026-11-24 | 177Lu-DOTATATE injection | HTA Co., Ltd. | Other | 184 | +0.0 mo |
| 2026-11-25 | ICP-332 Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Immuno | 552 | +0.0 mo |
| 2026-11-25 | rilzabrutinib | Sanofi $SNY | Cardio-Met | 3 | -0.2 mo |
| 2026-11-26 | RUBY | Tesaro, Inc. | Oncology | 785 | +60.0 mo |
| 2026-11-26 | MT1013 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Cardio-Met | 424 | +0.0 mo |
Registry changes · last 7 days
Phase 3 / 2-3 trials whose ClinicalTrials.gov record changed (status, readout date, enrollment, sites), plus stops and results posted.
Change tracking started on 2026-11-13 — the first day-over-day changes appear after the next nightly run.
Delay Index
Across 5,352 active trials registered more than a year ago, 46% have moved their readout date by more than 6 months since first registration.
Most often late
| Sponsor | Trials | >6 mo late |
|---|---|---|
| Acerta Pharma BV | 12 | 83% |
| Ionis Pharmaceuticals, Inc. $IONS | 12 | 83% |
| Taiho Oncology, Inc. | 10 | 70% |
| Allist Pharmaceuticals, Inc. | 12 | 67% |
| Seagen, a wholly owned subsidiary of Pfizer $PFE | 12 | 67% |
Most on time
| Sponsor | Trials | On time ±1 mo |
|---|---|---|
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. $1093.HK | 10 | 100% |
| Qilu Pharmaceutical Co., Ltd. | 33 | 88% |
| Ono Pharmaceutical Co., Ltd. $4528.T | 13 | 85% |
| Biocad | 12 | 83% |
| Shanghai JMT-Bio Inc. | 12 | 83% |
FDA this week
New NDA/BLA approvals and Class I drug recalls (last 7 days), and manufacturing (CGMP) or trial-conduct warning letters (last 14 days).
| Type | What | Company | Date |
|---|---|---|---|
| ✓ Approval | OXDERYS (doxorubicin hydrochloride) | AVYXA HOLDINGS | 2026-11-09 |
| ✓ Approval | NDA221291 | BAYER HEALTHCARE $BAYN.DE | 2026-11-09 |
| ✓ Approval | MULTIBIC (multibic) | FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC | 2026-11-09 |
| ✉ Warning letter | Request for Records/CGMP/API/Adulterated | Nanjing Hanxin Pharmaceutical Technology Co. Ltd. | 2026-11-03 |
| ✉ Warning letter | CGMP/Finished Pharmaceuticals/Adulterated | USV Private Limited | 2026-11-02 |
New Phase 3 trials · last 7 days
31 Phase 3 / 2-3 trials were first posted on ClinicalTrials.gov.
| Trial | Sponsor | Area | N |
|---|---|---|---|
| Frexalimab | Sanofi $SNY | Neuro | 2500 |
| AMBITION 3 | Novo Nordisk A/S $NVO | Cardio-Met | 1200 |
| AMBITION4 | Novo Nordisk A/S $NVO | Cardio-Met | 1060 |
| Berobenatide | Pfizer $PFE | Cardio-Met | 900 |
| RC118(Dose 1) plus RC148(Dose 1) | RemeGen Co., Ltd. | Oncology | 680 |
| SYS6010 | CSPC Megalith Biopharmaceutical Co.,Ltd. $1093.HK | Oncology | 585 |
| ABBV-722 | AbbVie $ABBV | Immuno | 580 |
| SHR-3167 Injection | Jiangsu HengRui Medicine Co., Ltd. $600276.SS | Cardio-Met | 450 |
| AMBITION 2 | Novo Nordisk A/S $NVO | Cardio-Met | 450 |
| SYS6010 combined with Enlonstobart | CSPC Megalith Biopharmaceutical Co.,Ltd. $1093.HK | Oncology | 424 |
| QLS5132 | Qilu Pharmaceutical Co., Ltd. | Oncology | 420 |
| SUMMIT OLE | United Therapeutics $UTHR | Cardio-Met | 400 |
| TLX101-Px | Telix Pharmaceuticals (Innovations) Pty Limited | Oncology | 381 |
| NP-101 | Novatek Pharmaceuticals | Oncology | 381 |
| RC28-E | RemeGen Co., Ltd. | Cardio-Met | 350 |
Post text
Ready to paste on LinkedIn or X.
📡 TrialSonar Radar Report · 13 Nov 2026 ⏱ 15 Phase 3 readouts due in the next 14 days (119 in 30): • 2026-11-13 — INAVO121 (Hoffmann-La Roche $ROG.SW, Oncology) • 2026-11-15 — ORCA-V2 (Achieve Life Sciences, Other) • 2026-11-18 — POETYK SjS-1 (Bristol-Myers Squibb $BMY, Immuno) • 2026-11-18 — Drugs-SNPs (Medicine Invention Design, Inc, Oncology) • 2026-11-20 — Pembrolizumab (Merck Sharp & Dohme LLC $MRK, Oncology) 📉 Delay Index: 46% of active trials (registered >1 yr ago) have pushed their readout >6 months. Most often late: Acerta Pharma BV 83%, Ionis Pharmaceuticals, Inc. 83%, Taiho Oncology, Inc. 70% ⚕ FDA: OXDERYS approved (AVYXA HOLDINGS); NDA221291 approved (BAYER HEALTHCARE); MULTIBIC approved (FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC); warning letter to Nanjing Hanxin Pharmaceutical Technology Co. Ltd.; warning letter to USV Private Limited Full report & live map: /report/ Data: ClinicalTrials.gov, openFDA, fda.gov. Not investment advice.
Sources: ClinicalTrials.gov (U.S. NLM), openFDA and fda.gov warning letters. Primary completion dates are sponsor-reported and often estimates; readout = last primary-endpoint data collected, not results publication. For information only — not investment or medical advice. Disclaimer